<DOC>
	<DOCNO>NCT02577393</DOCNO>
	<brief_summary>The investigator conduct phase II study EGCG therapy protection esophagus damage induce radiotherapy . In order observe effectiveness EGCG , esophageal toxicity record weekly use grade scale base symptomatology , follow Radiation Therapy Oncology Group ( RTOG ) score system . Patient-reported pain related esophagitis measure use numerical rating scale ( NRS ) every week EGCG application 2 week end radiotherapy . The scale translate Chinese guide Chinese develop instruct use scale perform assessment .</brief_summary>
	<brief_title>Study Epigallocatechin-3-gallate ( EGCG ) Esophagus Protection Patients With Lung Cancer Receiving Radial Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Be require seventh edition American Joint Committee Cancer ( AJCC ) stage IIIA consider medically inoperable , stage IIIB . Ageâ‰¥18 year Eastern Cooperative Oncology Group performance status 01 No prior systemic chemotherapy radiation thorax Adequate hematologic , hepatic function , renal value Forced expiratory volume1 &gt; 800 cc . Pregnancy lactation A known allergy hypersensitivity EGCG Patients mediastinal tumor metastatic lymph node invade esophagus The percentage esophagus volume receive 50 Gy ( V50 ) &lt; 30 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lung Neoplasms</keyword>
	<keyword>esophagitis</keyword>
	<keyword>Prevention &amp; Control</keyword>
	<keyword>Epigallocatechin Gallate</keyword>
</DOC>